Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas

N. Dusílková, P. Bašová, J. Polívka, O. Kodet, V. Kulvait, M. Pešta, M. Trněný, T. Stopka,

. 2017 ; 18 (10) : . [pub] 20171015

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024556

Grantová podpora
NV16-27790A MZ0 CEP - Centrální evidence projektů

Primary cutaneous T-cell lymphomas (CTCL) affect the skin and tend to transform and spread. CTCL involves primarily the Mycosis fungoides (MF) and more aggressive Sezary syndrome (SS). Oncogenic microRNAs (miRs) are stable epigenetic inhibitors often deregulated in the tumour and detectable as biomarkers in non-cellular fractions of peripheral blood. The tumour-specific expression of miR-155, miR-203, and miR-205 was shown to correctly diagnose CTCL. We herein asked whether these microRNAs can be used as plasma biomarkers for clinical CTCL monitoring. Patients with CTCL (n = 10) and controls with non-malignant conditions (n = 11) repeatedly donated plasma samples every ca. five months. MicroRNAs were detected in the plasma samples by specifically-primed RT-PCR followed by multivariate analyses of the miR expression dynamics. We herein established the plasma miR-classifier for detecting CTCL based on the miR-155 upregulation and miR-203/miR-205 downregulation with 100% specificity and 94% sensitivity. The 3-miR-score in the consecutive samples coincided with the clinical outcome of MF and SS patients such as the therapy response or changes in the clinical stage or tumor size. Quantitation of the selected microRNAs in plasma is a specific and straightforward approach for evaluating CTCL outcome representing, thus, a valuable tool for CTCL diagnostics and therapy response monitoring.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024556
003      
CZ-PrNML
005      
20180710095254.0
007      
ta
008      
180709s2017 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms18102136 $2 doi
035    __
$a (PubMed)29036928
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dusílková, Nina $u BIOCEV, First Faculty of Medicine, Charles University, 25250 Vestec, Czech Republic. nina.dusilkova@lf1.cuni.cz. Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 12853 Prague, Czech Republic. nina.dusilkova@lf1.cuni.cz.
245    10
$a Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas / $c N. Dusílková, P. Bašová, J. Polívka, O. Kodet, V. Kulvait, M. Pešta, M. Trněný, T. Stopka,
520    9_
$a Primary cutaneous T-cell lymphomas (CTCL) affect the skin and tend to transform and spread. CTCL involves primarily the Mycosis fungoides (MF) and more aggressive Sezary syndrome (SS). Oncogenic microRNAs (miRs) are stable epigenetic inhibitors often deregulated in the tumour and detectable as biomarkers in non-cellular fractions of peripheral blood. The tumour-specific expression of miR-155, miR-203, and miR-205 was shown to correctly diagnose CTCL. We herein asked whether these microRNAs can be used as plasma biomarkers for clinical CTCL monitoring. Patients with CTCL (n = 10) and controls with non-malignant conditions (n = 11) repeatedly donated plasma samples every ca. five months. MicroRNAs were detected in the plasma samples by specifically-primed RT-PCR followed by multivariate analyses of the miR expression dynamics. We herein established the plasma miR-classifier for detecting CTCL based on the miR-155 upregulation and miR-203/miR-205 downregulation with 100% specificity and 94% sensitivity. The 3-miR-score in the consecutive samples coincided with the clinical outcome of MF and SS patients such as the therapy response or changes in the clinical stage or tumor size. Quantitation of the selected microRNAs in plasma is a specific and straightforward approach for evaluating CTCL outcome representing, thus, a valuable tool for CTCL diagnostics and therapy response monitoring.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a nádorové biomarkery $7 D014408
650    _2
$a studie případů a kontrol $7 D016022
650    12
$a cirkulující mikroRNA $7 D000074166
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a tekutá biopsie $7 D000073890
650    _2
$a kožní T-buněčný lymfom $x krev $x diagnóza $x genetika $x terapie $7 D016410
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a kůže $x patologie $7 D012867
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bašová, Petra $u BIOCEV, First Faculty of Medicine, Charles University, 25250 Vestec, Czech Republic. basova.petra@gmail.com.
700    1_
$a Polívka, Jindřich $u Department of Haematology, First Faculty of Medicine, Charles University and General Hospital, 12808 Prague, Czech Republic. jinpol@gmail.com.
700    1_
$a Kodet, Ondřej $u BIOCEV, First Faculty of Medicine, Charles University, 25250 Vestec, Czech Republic. ondrej.kodet@lf1.cuni.cz. Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General Hospital, 12808 Prague, Czech Republic. ondrej.kodet@lf1.cuni.cz.
700    1_
$a Kulvait, Vojtěch $u BIOCEV, First Faculty of Medicine, Charles University, 25250 Vestec, Czech Republic. kulvait@gmail.com.
700    1_
$a Pešta, Michal $u Faculty of Mathematics and Physics, Charles University, 18675 Prague, Czech Republic. pesta@karlin.mff.cuni.cz.
700    1_
$a Trněný, Marek $u Department of Haematology, First Faculty of Medicine, Charles University and General Hospital, 12808 Prague, Czech Republic. trneny@cesnet.cz.
700    1_
$a Stopka, Tomáš $u BIOCEV, First Faculty of Medicine, Charles University, 25250 Vestec, Czech Republic. tstopka@lf1.cuni.cz. Department of Haematology, First Faculty of Medicine, Charles University and General Hospital, 12808 Prague, Czech Republic. tstopka@lf1.cuni.cz.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 18, č. 10 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29036928 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180710095544 $b ABA008
999    __
$a ok $b bmc $g 1316687 $s 1021477
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 18 $c 10 $e 20171015 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a NV16-27790A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace